Big Pharma’s Patent Abuses Are Fueling the Drug Pricing Crisis
The latest in news from I-MAK experts.
For press inquiries, please contact simon@i-mak.org.
Treatment Advocates Challenge Patent for New Hepatitis C Drug
Gilead Sciences’ Indian patent request for hepatitis C drug sofosbuvir faces opposition
US group seeks block on blockbuster Hep-C drug patent in India
I-MAK challenges Gilead sofosbuvir patent in India
I-MAK Opposes Patent Application on Hepatitis C Drug Sofosbuvir
Gilead Sofosbuvir Patent Meets Resistance in India
Advocates Try To Block Gilead Patent For Hep C Drug In India
I-MAK Files Patent Challenge on Hepatitis C drug Sofosbuvir in India
Gilead attempt to secure patent on hepatitis C drug opposed in India
Patent war: patients vs profit – Tahir Amin Discusses the Recent Novartis Decision on NDTV